The Trustees of Columbia University in The City of New York

Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901. “We are honored to add these prominent leaders of the retina community to our SAB as we approach the topline data readout of the Phase 2 PAVIA trial for non-proliferative diabetic retinopathy later this quarter, and as we prepare for the initiation of our global Phase 3 program in the second half of 2024,” said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint. “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion. The caliber of our expanded SAB speaks to the quality and potential of our programs, and I look forward to this collaboration to further expand our product candidates and to bring novel treatment options to patients globally.” “We are delighted to announce that ‘DURAVYU’ has been conditionally accepted as a proprietary name by the FDA for our lead product candidate, EYP-1901,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint. “This represents another step forward as we continue to advance DURAVYU through clinical development across three significant sight-threatening indications in our efforts to bring a safe and effective therapy with the potential to improve the treatment paradigm for patients.” “Following EyePoint’s strong and convincing Phase 2 DAVIO 2 data for DURAVYU in wet AMD, I am delighted to have these distinguished leaders on the cutting edge of ophthalmic research join the SAB,” said Carl Regillo, M.D., FACS, Co-Chair of EyePoint’s SAB. “I look forward to collaborating with Dr. Wykoff in his expanded role, as well as the renowned members of the SAB and EyePoint management team, as we work to improve the lives of patients with serious retinal diseases.” Usha Chakravarthy, M.B.B.S., Ph.D. Usha Chakravarthy, M.B.B.S., Ph.D. is an Honorary and Emerita Professor of Ophthalmology and Vision Sciences at the Queen’s University of Belfast. She is recognized internationally for her work on age-related macular degeneration (AMD) and diabetic retinopathy. Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad. She has been involved in many of the major international retina clinical trials as well as co-authored Cochrane Review articles and guidelines for the Royal College of Ophthalmologists on the treatment of AMD. Dr. Chakravarthy has been the recipient of many prestigious awards including the title of Commander in the Most Excellent Order of the British Empire for clinical services to ophthalmology and research. She holds a Ph.D. from Queen’s University of Belfast and an M.B.B.S. from the University of Madras. Allen Ho, M.D.,FACS FASRS Allen Ho, M.D. FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. He has deep experience in translational clinical research and maintains special interests in macular diseases, diabetic retinopathy, surgical retinal diseases and clinical trials, investigating new treatments for vitreoretinal diseases. Dr. Ho has authored over 300 peer reviewed publications and several textbooks. He has been a principal investigator on numerous major clinical trials developing new medical and surgical treatments for retinal disorders. Dr. Ho is the recipient of numerous awards including from the American Academy of Ophthalmology, multiple retina societies and the American Diabetes Association, and he is a perennial awardee of national Castle Connolly awards. He was also named in the Ophthalmologist Power List of the top 100 most influential ophthalmologists in the world. Dr. Ho holds an M.D. from Columbia University College of Physicians and Surgeons and a B.A. from Cornell University. Frank Holz, M.D., F.E.B.O., F.A.R.V.O. Frank Holz, M.D., F.E.B.O., F.A.R.V.O. is a professor and chairman of the Department of Ophthalmology at the University of Bonn in Germany. He founded the Medical Imaging Center Bonn (MIB), the GRADE Reading Center Bonn and was a co-founder of the Priority Program AMD of the German Research Council. He has published over 600 articles in peer-reviewed journals and has authored or co-authored more than 20 book chapters on age-related macular degeneration, medical retina and retinal imaging. Dr. Holz is the recipient of multiple local, national and international awards including the Pro Retina Macular Degeneration Research Award, the Leonhard-Klein Award for Ocular Surgery, the Alcon Research Institute (ARI) Award, the Senior Achievement Award of the AAO and the Jules Gonin Award. He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA. Dr. Holz trained at the University of Heidelberg, the University of Chicago Pritzker School of Medicine and completed a fellowship at Moorfields Eye Hospital, London. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. About EyePoint Pharmaceuticals EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, EYP-1901 (DURYVU™), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, f/k/a AKB-9778, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan. Forward Looking Statements EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for EYP-1901 (DURAVYU™) in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME); the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals including potential U.S. Food and Drug Administration (FDA) regulatory approval of DURAVYU and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; the success of Durasert® as a drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors: Christina Tartaglia Stern IR Direct: 212-698-8700 christina.tartaglia@sternir.com Media Contact: Amy Phillips Green Room Communications Direct: 412-327-9499 aphillips@greenroompr.com

Dr. Scott Braunstein, Chairman and CEO of Marinus Pharma and Operating Partner of Aisling Capital; and Dr. Vincent Miller, global expert in cancer, and clinical trial design and interpretation join ahead of One Biosciences’ pending initiation of drug development activities.PARIS, March 27, 2024 (GLOBE NEWSWIRE) -- One Biosciences, a Home Biosciences biotech company, leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and develop new treatments, today announced the appointments of Dr. Scott Braunstein, and Dr. Vincent Miller, to its Board of Directors. David Schilansky, co-founder and CEO of Home Biosciences and Chairman of One Biosciences, commented "It is a rare instance when a biotech company can anchor its board this quickly — in particular, with members of this caliber which speaks volumes of One Biosciences’ efforts to attract the very best talent in order to advance its mission. Scott and Vince join at a crucial time, as One Biosciences prepares to enter the drug development phase.” Hedi Ben Brahim, CEO of One Biosciences, added "One Biosciences is advancing its pipeline across multiple ongoing projects in oncology and rare diseases. Our proprietary discovery engine has identified its first promising targets, and we are preparing to start drug development activities in 2025. Bolstering our Board with such seasoned leaders will be a key factor to success.” Dr. Scott Braunstein brings over 30 years of knowledge and experience gained in the biotechnology, pharmaceutical, and biotech portfolio management industries. Since 2015, Dr. Braunstein has served as an Operating Partner of Aisling Capital. He is also CEO of Marinus Pharmaceuticals since 2019 and Chairman of the Board since November 2022. Previously, he was Chief Operating Officer and Chief Strategy Officer at Pacira Pharmaceuticals. Before Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management and spent 13 years with J.P. Morgan Asset Management where he was a healthcare analyst and managing director in the U.S. Equity team, and a portfolio manager of the JP Morgan Global Healthcare Fund. Dr. Braunstein is currently on the board at Trevena and Caribou Biosciences. He previously served on the boards of Constellation Pharmaceuticals (acquired by MorphoSys in July 2021), Ziopharm Oncology, Esperion Therapeutics, and Protara Therapeutics. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as an Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University. Dr. Vincent Miller is considered a world-expert in lung cancer and clinical trial design and interpretation. His role in collaborative research was critical to identifying certain EGFR mutations as the molecular basis of sensitivity and resistance to first-generation EGFR TKIs. Among his many accolades, Dr. Miller received the American Cancer Society Clinical Oncology Career Development Award. Dr. Miller has previously served as Physician-in-Chief, EQRx. and prior to that he served as Chief Medical Officer at Foundation Medicine. Before joining Foundation Medicine, Dr. Miller dedicated over 20 years to cancer patient care and research at Memorial Sloan Kettering Cancer Center. He has also served as Chief Medical Resident at Thomas Jefferson University Hospital where he completed his residency and fellowship at Memorial Sloan Kettering Cancer Center. Dr. Miller received his B.A. from the University of Pennsylvania and M.D. from New Jersey Medical School. About One Biosciences One Biosciences leverages the power of single-cell analysis and AI to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences. For more information, visit: www.onebiosciences.fr US press for One Biosciences McCargo Mission-Aligned CommunicationsJanine McCargojanine@mmac.me

What would you do if you walked up to a robot with a human-like head and it smiled at you first? You'd likely smile back and perhaps feel the two of you were genuinely interacting. But how does a robot know how to do this? Or a better question, how does it know to get you to smile back? What would you do if you walked up to a robot with a human-like head and it smiled at you first? You'd likely smile back and perhaps feel the two of you were genuinely interacting. But how does a robot know how to do this? Or a better question, how does it know to get you to smile back? While we're getting accustomed to robots that are adept at verbal communication, thanks in part to advancements in large language models like ChatGPT, their nonverbal communication skills, especially facial expressions, have lagged far behind. Designing a robot that can not only make a wide range of facial expressions but also know when to use them has been a daunting task. Tackling the challenge The Creative Machines Lab at Columbia Engineering has been working on this challenge for more than five years. In a new study published today in Science Robotics, the group unveils Emo, a robot that anticipates facial expressions and executes them simultaneously with a human. It has even learned to predict a forthcoming smile about 840 milliseconds before the person smiles, and to co-express the smile simultaneously with the person. The team, led by Hod Lipson, a leading researcher in the fields of artificial intelligence (AI) and robotics, faced two challenges: how to mechanically design an expressively versatile robotic face which involves complex hardware and actuation mechanisms, and knowing which expression to generate so that they appear natural, timely, and genuine. The team proposed training a robot to anticipate future facial expressions in humans and execute them simultaneously with a person. The timing of these expressions was critical -- delayed facial mimicry looks disingenuous, but facial co-expression feels more genuine since it requires correctly inferring the human's emotional state for timely execution. How Emo connects with you Emo is a human-like head with a face that is equipped with 26 actuators that enable a broad range of nuanced facial expressions. The head is covered with a soft silicone skin with a magnetic attachment system, allowing for easy customization and quick maintenance. For more lifelike interactions, the researchers integrated high-resolution cameras within the pupil of each eye, enabling Emo to make eye contact, crucial for nonverbal communication. The team developed two AI models: one that predicts human facial expressions by analyzing subtle changes in the target face and another that generates motor commands using the corresponding facial expressions. To train the robot how to make facial expressions, the researchers put Emo in front of the camera and let it do random movements. After a few hours, the robot learned the relationship between their facial expressions and the motor commands -- much the way humans practice facial expressions by looking in the mirror. This is what the team calls "self modeling" -- similar to our human ability to imagine what we look like when we make certain expressions. Then the team ran videos of human facial expressions for Emo to observe them frame by frame. After training, which lasts a few hours, Emo could predict people's facial expressions by observing tiny changes in their faces as they begin to form an intent to smile. "I think predicting human facial expressions accurately is a revolution in HRI. Traditionally, robots have not been designed to consider humans' expressions during interactions. Now, the robot can integrate human facial expressions as feedback," said the study's lead author Yuhang Hu, who is a PhD student at Columbia Engineering in Lipson's lab. "When a robot makes co-expressions with people in real-time, it not only improves the interaction quality but also helps in building trust between humans and robots. In the future, when interacting with a robot, it will observe and interpret your facial expressions, just like a real person." What's next The researchers are now working to integrate verbal communication, using a large language model like ChatGPT into Emo. As robots become more capable of behaving like humans, Lipson is well aware of the ethical considerations associated with this new technology. "Although this capability heralds a plethora of positive applications, ranging from home assistants to educational aids, it is incumbent upon developers and users to exercise prudence and ethical considerations," says Lipson, James and Sally Scapa Professor of Innovation in the Department of Mechanical Engineering at Columbia Engineering, co-director of the Makerspace at Columbia, and a member of the Data Science Institute. "But it's also very exciting -- by advancing robots that can interpret and mimic human expressions accurately, we're moving closer to a future where robots can seamlessly integrate into our daily lives, offering companionship, assistance, and even empathy. Imagine a world where interacting with a robot feels as natural and comfortable as talking to a friend."